Thu.Sep 26, 2024

article thumbnail

STAT+: What Pfizer’s decision to pull its sickle cell drug means for patients, the company, and the FDA

STAT

Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to notify their patients about a drug that has long divided the community.  The move underscored the severity of the risks recently seen in studies of the drug, Oxbryta , in which researchers have reported a number of deaths among patients who were receiving it.

340
340
article thumbnail

Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters

PharmaVoice

Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.

162
162
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Sleep apnea alert on Apple Watch: What does it mean, and how does it work?

STAT

This month, Apple launched a feature for the Apple Watch that alerts users if it determines they may have sleep apnea, potentially leading to treatment for a dangerous health condition that often goes undiagnosed.  Some see this as a good thing: Untreated sleep apnea, a condition where breathing is repeatedly disrupted during sleep, can result in persistent daytime tiredness and in the worst cases, cardiovascular diseases that hasten death.

331
331
article thumbnail

Behind the rise BMS’ KarXT, the first new schizophrenia drug in decades

PharmaVoice

KarXT’s approval demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.

130
130
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

STAT+: FDA approves schizophrenia drug that could alter how disorder is treated

STAT

For decades, doctors caring for people with schizophrenia have relied on mood-regulating drugs that target the brain chemical dopamine. On Thursday, the Food and Drug Administration approved for the first time a new type of medicine that may change the way the psychiatric disorder is treated.  The drug, called Cobenfy, will be sold by Bristol Myers Squibb.

327
327
article thumbnail

Bristol Myers schizophrenia drug, the first of its kind, approved by FDA

BioPharma Dive

In testing, Cobenfy eased schizophrenia symptoms without some of the disruptive side effects typical of existing drugs. The results have been met with excitement, as well as caution.

124
124

More Trending

article thumbnail

Vicebio raises $100m for vaccines and other bio financings

pharmaphorum

Our periodic round-up of financings in the biotech sector is led by an impressive nine-figure round for UK vaccines developer Vicebio, with GC Therapeutics, Genespire, and 858 Therapeutics also in on the action.London, UK-based Vicebio raised $100 million in a Series B that will help to fund the development of its Molecular Clamp technology to produce improved, more potent vaccines that are simpler to manufacture.

Vaccines 109
article thumbnail

STAT+: ARCH Venture Partners raises $3 billion for a new biotech fund

STAT

ARCH Venture Partners has raised $3 billion for a new fund — one of the largest in the biotech industry, and one the VC firm will use to continue its contrarian investment strategy.  The last few years have tested many venture firms: biotech stocks dropped, valuations shifted, and the flow of fresh capital forced many startups out of business before signs of a recovery emerged.

306
306
article thumbnail

Some LPCs securing funding for Pharmacy First 'engagement'

The Pharmacist

Some Local Pharmaceutical Committees (LPCs) have secured funding to ‘facilitate direct engagement’ between pharmacies and GP practices around Pharmacy First, according to a new report from the Company Chemists’ Association. The funding from NHS England regions and integrated care systems (ICSs) has been used by one LPC to fund full-time staff to support engagement around […] The post Some LPCs securing funding for Pharmacy First 'engagement' appeared first on The Pharmacist.

108
108
article thumbnail

STAT+: Epic Systems has been challenged in court before, but its different this time

STAT

Epic Systems is no stranger to the courtroom. The nation’s largest vendor of electronic health records has fought, and won, legal fights with rivals large and small for many decades. But a new antitrust lawsuit filed this week by Particle Health , an upstart health data company, presents an especially direct threat to Epic’s dominance in the multi-billion dollar market surrounding patient data, legal and health policy experts told STAT.

300
300
article thumbnail

Grow Big, Pay Smart: How To Unlock Efficiency In Payroll Management

Speaker: Joe Sharpe and James Carlson

Running a small business is no small feat. Payroll management, in particular, can be one of the most time-consuming and complex parts of that equation. Yet, businesses that crack the code on streamlining these processes often discover not just savings, but new avenues for growth. Our expert speakers will share actionable insights and real-world examples of how businesses have reduced overhead and improved payroll efficiency.

article thumbnail

Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science

BioPharma Dive

Despite working in a restrictive funding climate, the prolific startup creator is “in the ‘taking lots of risk’ mode,” said co-founder and managing director Robert Nelsen.

104
104
article thumbnail

STAT+: Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines

STAT

Facing charges from the Securities and Exchange Commission for misleading claims related to a controversial Alzheimer’s drug candidate, Cassava Sciences and two of the company’s former executives have agreed to pay fines, the company announced Thursday. The news comes on the same day that the SEC filed charges against Cassava, former CEO Remi Barbier, and former senior vice president of neuroscience Lindsay Burns.

286
286
article thumbnail

Mirai Bio launches with plan to help genetic med developers

pharmaphorum

Flagship Pioneering's latest biotech launch, Mirai Bio, aims to help genetic medicine developers find the best way to get their drugs to patients.The new Cambridge, Massachusetts-based company – which was set up in 2021 but makes its official launch today with $50 million in funding from Flagship – applies artificial intelligence to solve the various obstacles that can block the progress of new medicines.

99
article thumbnail

STAT+: FDA introduces plan to assess safety of common chemicals added to food

STAT

SILVER SPRING, Md. — Food additives rarely face FDA scrutiny once they’re on the market, even those with mounting evidence of safety concerns. At a meeting held by the Food and Drug Administration on Wednesday, regulators said they plan to change that.  The public meeting on the FDA’s campus drew dozens of food safety advocates, industry representatives, concerned citizens, and state and federal lawmakers.

Packaging 273
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Obesity drug developer BioAge raises $198m in IPO

pharmaphorum

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive investor appetite for companies with assets in the clinic for obesity and takes the on-paper value of the Richmond, California-based company above $600 million.

article thumbnail

STAT+: Head of national stockpile addresses Congress’ criticisms of outbreak response

STAT

WASHINGTON — Pushing back on complaints from Congress this year that her agency’s response to disease outbreaks was sluggish, Dawn O’Connell forcefully defended the Administration for Strategic Preparedness and Response at a STAT event in D.C.  Congress has “extraordinary confidence in our ability to deliver,” she said Thursday, pointing to recent budget increases for ASPR in House and Senate markups of the 2025 Labor and HHS appropriations bill.

255
255
article thumbnail

AZ gets sought-after lung cancer approval for Tagrisso

pharmaphorum

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targeted treatments. The US regulator has cleared Tagrisso (osimertinib) for patients with stage 3 non-small cell lung cancer (NSCLC) expressing EGFR exon 19 or exon 21 (L858R) mutations that cannot be treated with surgery and has been previously treated with chemoradiotherapy.

91
article thumbnail

Opinion: Congress must reauthorize the Older Americans Act to keep seniors safe from heat

STAT

On Wednesday, Congress passed a temporary spending bill that keeps the government funded beyond Sept. 30. Yet, even in light of lawmakers averting a shutdown, there is another end-of-moth deadline looming they’ve largely ignored: expiration of foundational aging and disability legislation called the Older Americans Act (OAA). The OAA supports the delivery of home and community-based social and services that improve the lives, dignity, safety and wellbeing of older adults.

Packaging 236
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Evotec and Novo Nordisk in technology development partnership

Express Pharma

German drug and development company Evotec, has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, Evotec said on Thursday. Evotec will receive funding for technology development activities in Germany and Italy, research and development funding, an undisclosed upfront payment and possible milestone and royalty payments, it added.

article thumbnail

STAT+: Two reports, two dramatically different views of nonprofit hospitals’ tax breaks

STAT

Within a few days of one another, two teams of accountants released separate estimates on the value of nonprofit hospitals’ tax exemptions. Their wildly different findings underscore the degree to which who’s counting and what they count matters.  The first, a JAMA study published today , pegged that number at $37.4 billion. It factored in the value of forgone federal and state income taxes, sales tax, property tax, federal unemployment tax, charitable contributions from donor

Hospitals 232
article thumbnail

Second Niemann-Pick approval brings more hope to patients

pharmaphorum

IntraBio claims FDA approval for its Aqneursa therapy for Niemann-Pick type C, the second new drug for the disease in four days

105
105
article thumbnail

Genentech’s cancer pivot, Pfizer’s sickle cell withdrawal, and a new schizophrenia drug

STAT

Why are Genentech’s cancer researchers concerned about the direction of the company? What led Pfizer to pull its sickle cell drug off global markets? And what cake did Adam make for all his podcast colleagues except Elaine? We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

233
233
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Bhushan Akshikar appointed OPPI President

Express Pharma

The Organisation of Pharmaceutical Producers of India (OPPI) has appointed Bhushan Akshikar as its President for a two-year term, effective from 26 September 2024. OPPI, representing global research-based pharmaceutical companies in India, will benefit from Bhushan’s extensive experience in the industry. Bhushan Akshikar has over 13 years of leadership experience with GSK in regions including India, the Middle East, Russia, CIS, and Africa.

article thumbnail

STAT+: Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more

STAT

Rise and shine, everyone, another busy day is on the way. However, this is shaping up as a lovely day as well, despite forecasts suggesting a smattering of rain a few hours from now. For the moment, the skies are tranquil, the birds are chirping, and the official mascots are hunting for noshes on the Pharmalot campus. This calls for celebration with a cup of stimulation, and we are reaching for pecan pie — sweets for the sweet.

Vaccines 233
article thumbnail

MSD hits a hurdle with its LAG-3 programme

pharmaphorum

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable (MSS) metastatic colorectal cancer.An analysis of data from the 447-patient KEYFORM-007 study revealed that the fixed-dose combination of Keytruda (pembrolizumab) and favezelimab was unable to extend overall survival (OS) compared to standard care with kinase inhibitor regorafenib and trifluridine and tipirac

article thumbnail

STAT+: Why Biohaven will test the FDA’s regulatory limits  

STAT

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered to their inbox. I love a good regulatory debate. Biohaven Pharmaceuticals has given us a new one to chew over.  On Monday, the company said it planned to  submit a marketing application  to the Food and Drug Administration before the end of the year, seeking approval for an experimental drug called troriluzole to delay progr

220
220
article thumbnail

Merck’s colorectal cancer therapy fails late-stage trial

Express Pharma

Merck, said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously treated patients with a type of colorectal cancer. This is the latest failure in a set of trials studying a combination involving Keytruda at a time the drugmaker seeks to expand its use in types of cancers not yet treated by immunotherapies while facing a loss of patent protection for the drug at the end of the decade.

article thumbnail

Higher buprenorphine doses prevent hospitalization of people with fentanyl addiction, study finds

STAT

Patients who received higher doses of buprenorphine, a common medication used to alleviate opioid withdrawal and cravings, were less likely to be hospitalized and less likely to discontinue treatment, according to a new study.  The findings run counter to federal guidelines about buprenorphine dosing. Currently, the Food and Drug Administration recommends a target dose of 16 mg.

Hospitals 215
article thumbnail

10th Annual Pharma Legal & Compliance Summit to be held in Mumbai

Express Pharma

The 10th Annual Pharma Legal & Compliance Summit (PLCS) 2024 will bring together key figures from the pharmaceutical, healthcare, and medical device industries for a day focused on regulatory insights, legal updates, and expert discussions. Organised by Lex Witness, India’s premier legal publication, the summit will take place on October 25, 2024, at Taj Santacruz, Mumbai.

article thumbnail

STAT+: Medicare will continue its cautious approach to paying for Alzheimer’s drugs

STAT

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. AAM picks up laid-off BIO exec Redox reactions – when an atom loses an electron that is picked up by another atom– are common to some basic functions of life, including photosynthesis, respiration, combustion.

210
210
article thumbnail

Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns

Outsourcing Pharma

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events.

75
article thumbnail

STAT+: Gene therapy for sickle cell disease remains a tough business model — and may never work

STAT

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered to their inbox. The  deep financial restructuring  announced by Bluebird Bio this week offered another reminder that groundbreaking genetic medicines capable of transforming the lives of people with inherited disease are not now — and may never become — a sustainable business.

210
210